Jiangsu Hengrui Pharmaceuticals (01276): SHR-4610 injection obtained drug clinical trial approval letter.

Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceuticals Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection. The clinical trial will begin soon. SHR-4610 injection is an innovative anti-tumor drug developed by the company, showing good anti-tumor activity in preclinical animal models. It is intended for the treatment of advanced solid tumors. As of now, the accumulated research and development investment for the SHR-4610 injection project is approximately 7.36 million yuan.